Global Active Pharmaceutical Ingredients (API) CDMO Market Growth (Status and Outlook) 2026-2032
The global Active Pharmaceutical Ingredients (API) CDMO market size is predicted to grow from US$ 65750 million in 2025 to US$ 115230 million in 2032; it is expected to grow at a CAGR of 8.5% from 2026 to 2032.
Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides services related to the development, manufacturing, and supply of active pharmaceutical ingredients used in the formulation of pharmaceutical products. API CDMOs play a crucial role in the pharmaceutical industry by assisting pharmaceutical companies in bringing their drug products to market efficiently and cost-effectively.
The global market for Active Pharmaceutical Ingredients (API) Contract Development and Manufacturing Organization (CDMO) services has experienced significant growth in recent years. API CDMOs play a critical role in the pharmaceutical industry by offering specialized expertise and capabilities in API development and manufacturing. The expanding pharmaceutical sector, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical treatments, has fueled the demand for API CDMO services. Pharmaceutical companies have increasingly turned to API CDMOs for cost-effective and time-efficient solutions, enabling them to focus on core competencies, research, and commercialization. The United States and Canada are major consumers of API CDMO services due to a large number of pharmaceutical companies and a robust drug development landscape. European countries, including the United Kingdom, Germany, and Switzerland, have a well-established pharmaceutical industry, contributing to significant demand for API CDMO services. Countries like India, China, and South Korea have emerged as major players in the API CDMO market, offering cost-competitive services and a skilled workforce. The global market for API CDMO services is expected to continue its growth trajectory in the coming years. As pharmaceutical companies seek to streamline their drug development processes, reduce costs, and access specialized expertise, API CDMOs will play a pivotal role in supporting the industry. Moreover, as the pharmaceutical landscape continues to evolve with the introduction of innovative therapies and biologics, API CDMOs will likely invest in advanced technologies and expand their service offerings to cater to the evolving needs of pharmaceutical companies.
LPI (LP Information)' newest research report, the “Active Pharmaceutical Ingredients (API) CDMO Industry Forecast” looks at past sales and reviews total world Active Pharmaceutical Ingredients (API) CDMO sales in 2025, providing a comprehensive analysis by region and market sector of projected Active Pharmaceutical Ingredients (API) CDMO sales for 2026 through 2032. With Active Pharmaceutical Ingredients (API) CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Active Pharmaceutical Ingredients (API) CDMO industry.
This Insight Report provides a comprehensive analysis of the global Active Pharmaceutical Ingredients (API) CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Active Pharmaceutical Ingredients (API) CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Active Pharmaceutical Ingredients (API) CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Active Pharmaceutical Ingredients (API) CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Active Pharmaceutical Ingredients (API) CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Active Pharmaceutical Ingredients (API) CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides services related to the development, manufacturing, and supply of active pharmaceutical ingredients used in the formulation of pharmaceutical products. API CDMOs play a crucial role in the pharmaceutical industry by assisting pharmaceutical companies in bringing their drug products to market efficiently and cost-effectively.
The global market for Active Pharmaceutical Ingredients (API) Contract Development and Manufacturing Organization (CDMO) services has experienced significant growth in recent years. API CDMOs play a critical role in the pharmaceutical industry by offering specialized expertise and capabilities in API development and manufacturing. The expanding pharmaceutical sector, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical treatments, has fueled the demand for API CDMO services. Pharmaceutical companies have increasingly turned to API CDMOs for cost-effective and time-efficient solutions, enabling them to focus on core competencies, research, and commercialization. The United States and Canada are major consumers of API CDMO services due to a large number of pharmaceutical companies and a robust drug development landscape. European countries, including the United Kingdom, Germany, and Switzerland, have a well-established pharmaceutical industry, contributing to significant demand for API CDMO services. Countries like India, China, and South Korea have emerged as major players in the API CDMO market, offering cost-competitive services and a skilled workforce. The global market for API CDMO services is expected to continue its growth trajectory in the coming years. As pharmaceutical companies seek to streamline their drug development processes, reduce costs, and access specialized expertise, API CDMOs will play a pivotal role in supporting the industry. Moreover, as the pharmaceutical landscape continues to evolve with the introduction of innovative therapies and biologics, API CDMOs will likely invest in advanced technologies and expand their service offerings to cater to the evolving needs of pharmaceutical companies.
LPI (LP Information)' newest research report, the “Active Pharmaceutical Ingredients (API) CDMO Industry Forecast” looks at past sales and reviews total world Active Pharmaceutical Ingredients (API) CDMO sales in 2025, providing a comprehensive analysis by region and market sector of projected Active Pharmaceutical Ingredients (API) CDMO sales for 2026 through 2032. With Active Pharmaceutical Ingredients (API) CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Active Pharmaceutical Ingredients (API) CDMO industry.
This Insight Report provides a comprehensive analysis of the global Active Pharmaceutical Ingredients (API) CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Active Pharmaceutical Ingredients (API) CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Active Pharmaceutical Ingredients (API) CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Active Pharmaceutical Ingredients (API) CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Active Pharmaceutical Ingredients (API) CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Active Pharmaceutical Ingredients (API) CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Macromolecular API
- Small Molecule API
- Clinical
- Commercial
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Recipharm
- Cambrex Corporation
- Patheon (Thermo Fisher Scientific)
- CordenPharma
- Lonza
- Siegfried
- Catalent
- Boehringer Ingelheim
- Piramal Group
- AbbVie
- SGS Quay Pharmaceuticals
- Aenova Group
- Curia
- Sterling Pharma Solutions
- Eurofins CDMO
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size (2021-2032)
2.1.2 Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Active Pharmaceutical Ingredients (API) CDMO by Country/Region (2021, 2025 & 2032)
2.2 Active Pharmaceutical Ingredients (API) CDMO Segment by Type
2.2.1 Macromolecular API
2.2.2 Small Molecule API
2.2.3 Active Pharmaceutical Ingredients (API) CDMO Market Size by Type
2.2.3.1 Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
2.3 Active Pharmaceutical Ingredients (API) CDMO Segment by Application
2.3.1 Clinical
2.3.2 Commercial
2.3.3 Others
2.3.4 Active Pharmaceutical Ingredients (API) CDMO Market Size by Application
2.3.4.1 Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
3 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET SIZE BY PLAYER
3.1 Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Player
3.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Revenue by Player (2021-2026)
3.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Player (2021-2026)
3.2 Global Active Pharmaceutical Ingredients (API) CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO BY REGION
4.1 Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2021-2026)
4.2 Global Active Pharmaceutical Ingredients (API) CDMO Annual Revenue by Country/Region (2021-2026)
4.3 Americas Active Pharmaceutical Ingredients (API) CDMO Market Size Growth (2021-2026)
4.4 APAC Active Pharmaceutical Ingredients (API) CDMO Market Size Growth (2021-2026)
4.5 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Growth (2021-2026)
4.6 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2021-2026)
5.2 Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026)
5.3 Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2021-2026)
6.2 APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026)
6.3 APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2021-2026)
7.2 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026)
7.3 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO by Region (2021-2026)
8.2 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026)
8.3 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET FORECAST
10.1 Global Active Pharmaceutical Ingredients (API) CDMO Forecast by Region (2027-2032)
10.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Forecast by Region (2027-2032)
10.1.2 Americas Active Pharmaceutical Ingredients (API) CDMO Forecast
10.1.3 APAC Active Pharmaceutical Ingredients (API) CDMO Forecast
10.1.4 Europe Active Pharmaceutical Ingredients (API) CDMO Forecast
10.1.5 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Forecast
10.2 Americas Active Pharmaceutical Ingredients (API) CDMO Forecast by Country (2027-2032)
10.2.1 United States Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.2.2 Canada Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.2.3 Mexico Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.2.4 Brazil Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.3 APAC Active Pharmaceutical Ingredients (API) CDMO Forecast by Region (2027-2032)
10.3.1 China Active Pharmaceutical Ingredients (API) CDMO Market Forecast
10.3.2 Japan Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.3.3 Korea Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.3.4 Southeast Asia Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.3.5 India Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.3.6 Australia Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.4 Europe Active Pharmaceutical Ingredients (API) CDMO Forecast by Country (2027-2032)
10.4.1 Germany Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.4.2 France Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.4.3 UK Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.4.4 Italy Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.4.5 Russia Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.5 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Forecast by Region (2027-2032)
10.5.1 Egypt Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.5.2 South Africa Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.5.3 Israel Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.5.4 Turkey Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.6 Global Active Pharmaceutical Ingredients (API) CDMO Forecast by Type (2027-2032)
10.7 Global Active Pharmaceutical Ingredients (API) CDMO Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Active Pharmaceutical Ingredients (API) CDMO Forecast
11 KEY PLAYERS ANALYSIS
11.1 Recipharm
11.1.1 Recipharm Company Information
11.1.2 Recipharm Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Recipharm Main Business Overview
11.1.5 Recipharm Latest Developments
11.2 Cambrex Corporation
11.2.1 Cambrex Corporation Company Information
11.2.2 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Cambrex Corporation Main Business Overview
11.2.5 Cambrex Corporation Latest Developments
11.3 Patheon (Thermo Fisher Scientific)
11.3.1 Patheon (Thermo Fisher Scientific) Company Information
11.3.2 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Patheon (Thermo Fisher Scientific) Main Business Overview
11.3.5 Patheon (Thermo Fisher Scientific) Latest Developments
11.4 CordenPharma
11.4.1 CordenPharma Company Information
11.4.2 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 CordenPharma Main Business Overview
11.4.5 CordenPharma Latest Developments
11.5 Lonza
11.5.1 Lonza Company Information
11.5.2 Lonza Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Lonza Main Business Overview
11.5.5 Lonza Latest Developments
11.6 Siegfried
11.6.1 Siegfried Company Information
11.6.2 Siegfried Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Siegfried Main Business Overview
11.6.5 Siegfried Latest Developments
11.7 Catalent
11.7.1 Catalent Company Information
11.7.2 Catalent Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Catalent Main Business Overview
11.7.5 Catalent Latest Developments
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Company Information
11.8.2 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Boehringer Ingelheim Main Business Overview
11.8.5 Boehringer Ingelheim Latest Developments
11.9 Piramal Group
11.9.1 Piramal Group Company Information
11.9.2 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Piramal Group Main Business Overview
11.9.5 Piramal Group Latest Developments
11.10 AbbVie
11.10.1 AbbVie Company Information
11.10.2 AbbVie Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 AbbVie Main Business Overview
11.10.5 AbbVie Latest Developments
11.11 SGS Quay Pharmaceuticals
11.11.1 SGS Quay Pharmaceuticals Company Information
11.11.2 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 SGS Quay Pharmaceuticals Main Business Overview
11.11.5 SGS Quay Pharmaceuticals Latest Developments
11.12 Aenova Group
11.12.1 Aenova Group Company Information
11.12.2 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Aenova Group Main Business Overview
11.12.5 Aenova Group Latest Developments
11.13 Curia
11.13.1 Curia Company Information
11.13.2 Curia Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Curia Main Business Overview
11.13.5 Curia Latest Developments
11.14 Sterling Pharma Solutions
11.14.1 Sterling Pharma Solutions Company Information
11.14.2 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Sterling Pharma Solutions Main Business Overview
11.14.5 Sterling Pharma Solutions Latest Developments
11.15 Eurofins CDMO
11.15.1 Eurofins CDMO Company Information
11.15.2 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Eurofins CDMO Main Business Overview
11.15.5 Eurofins CDMO Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size (2021-2032)
2.1.2 Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Active Pharmaceutical Ingredients (API) CDMO by Country/Region (2021, 2025 & 2032)
2.2 Active Pharmaceutical Ingredients (API) CDMO Segment by Type
2.2.1 Macromolecular API
2.2.2 Small Molecule API
2.2.3 Active Pharmaceutical Ingredients (API) CDMO Market Size by Type
2.2.3.1 Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
2.3 Active Pharmaceutical Ingredients (API) CDMO Segment by Application
2.3.1 Clinical
2.3.2 Commercial
2.3.3 Others
2.3.4 Active Pharmaceutical Ingredients (API) CDMO Market Size by Application
2.3.4.1 Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
3 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET SIZE BY PLAYER
3.1 Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Player
3.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Revenue by Player (2021-2026)
3.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Player (2021-2026)
3.2 Global Active Pharmaceutical Ingredients (API) CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO BY REGION
4.1 Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2021-2026)
4.2 Global Active Pharmaceutical Ingredients (API) CDMO Annual Revenue by Country/Region (2021-2026)
4.3 Americas Active Pharmaceutical Ingredients (API) CDMO Market Size Growth (2021-2026)
4.4 APAC Active Pharmaceutical Ingredients (API) CDMO Market Size Growth (2021-2026)
4.5 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Growth (2021-2026)
4.6 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2021-2026)
5.2 Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026)
5.3 Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2021-2026)
6.2 APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026)
6.3 APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2021-2026)
7.2 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026)
7.3 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO by Region (2021-2026)
8.2 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026)
8.3 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS (API) CDMO MARKET FORECAST
10.1 Global Active Pharmaceutical Ingredients (API) CDMO Forecast by Region (2027-2032)
10.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Forecast by Region (2027-2032)
10.1.2 Americas Active Pharmaceutical Ingredients (API) CDMO Forecast
10.1.3 APAC Active Pharmaceutical Ingredients (API) CDMO Forecast
10.1.4 Europe Active Pharmaceutical Ingredients (API) CDMO Forecast
10.1.5 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Forecast
10.2 Americas Active Pharmaceutical Ingredients (API) CDMO Forecast by Country (2027-2032)
10.2.1 United States Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.2.2 Canada Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.2.3 Mexico Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.2.4 Brazil Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.3 APAC Active Pharmaceutical Ingredients (API) CDMO Forecast by Region (2027-2032)
10.3.1 China Active Pharmaceutical Ingredients (API) CDMO Market Forecast
10.3.2 Japan Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.3.3 Korea Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.3.4 Southeast Asia Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.3.5 India Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.3.6 Australia Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.4 Europe Active Pharmaceutical Ingredients (API) CDMO Forecast by Country (2027-2032)
10.4.1 Germany Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.4.2 France Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.4.3 UK Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.4.4 Italy Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.4.5 Russia Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.5 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Forecast by Region (2027-2032)
10.5.1 Egypt Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.5.2 South Africa Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.5.3 Israel Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.5.4 Turkey Market Active Pharmaceutical Ingredients (API) CDMO Forecast
10.6 Global Active Pharmaceutical Ingredients (API) CDMO Forecast by Type (2027-2032)
10.7 Global Active Pharmaceutical Ingredients (API) CDMO Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Active Pharmaceutical Ingredients (API) CDMO Forecast
11 KEY PLAYERS ANALYSIS
11.1 Recipharm
11.1.1 Recipharm Company Information
11.1.2 Recipharm Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Recipharm Main Business Overview
11.1.5 Recipharm Latest Developments
11.2 Cambrex Corporation
11.2.1 Cambrex Corporation Company Information
11.2.2 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Cambrex Corporation Main Business Overview
11.2.5 Cambrex Corporation Latest Developments
11.3 Patheon (Thermo Fisher Scientific)
11.3.1 Patheon (Thermo Fisher Scientific) Company Information
11.3.2 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Patheon (Thermo Fisher Scientific) Main Business Overview
11.3.5 Patheon (Thermo Fisher Scientific) Latest Developments
11.4 CordenPharma
11.4.1 CordenPharma Company Information
11.4.2 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 CordenPharma Main Business Overview
11.4.5 CordenPharma Latest Developments
11.5 Lonza
11.5.1 Lonza Company Information
11.5.2 Lonza Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Lonza Main Business Overview
11.5.5 Lonza Latest Developments
11.6 Siegfried
11.6.1 Siegfried Company Information
11.6.2 Siegfried Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Siegfried Main Business Overview
11.6.5 Siegfried Latest Developments
11.7 Catalent
11.7.1 Catalent Company Information
11.7.2 Catalent Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Catalent Main Business Overview
11.7.5 Catalent Latest Developments
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Company Information
11.8.2 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Boehringer Ingelheim Main Business Overview
11.8.5 Boehringer Ingelheim Latest Developments
11.9 Piramal Group
11.9.1 Piramal Group Company Information
11.9.2 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Piramal Group Main Business Overview
11.9.5 Piramal Group Latest Developments
11.10 AbbVie
11.10.1 AbbVie Company Information
11.10.2 AbbVie Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 AbbVie Main Business Overview
11.10.5 AbbVie Latest Developments
11.11 SGS Quay Pharmaceuticals
11.11.1 SGS Quay Pharmaceuticals Company Information
11.11.2 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 SGS Quay Pharmaceuticals Main Business Overview
11.11.5 SGS Quay Pharmaceuticals Latest Developments
11.12 Aenova Group
11.12.1 Aenova Group Company Information
11.12.2 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Aenova Group Main Business Overview
11.12.5 Aenova Group Latest Developments
11.13 Curia
11.13.1 Curia Company Information
11.13.2 Curia Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Curia Main Business Overview
11.13.5 Curia Latest Developments
11.14 Sterling Pharma Solutions
11.14.1 Sterling Pharma Solutions Company Information
11.14.2 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Sterling Pharma Solutions Main Business Overview
11.14.5 Sterling Pharma Solutions Latest Developments
11.15 Eurofins CDMO
11.15.1 Eurofins CDMO Company Information
11.15.2 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product Offered
11.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Eurofins CDMO Main Business Overview
11.15.5 Eurofins CDMO Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Active Pharmaceutical Ingredients (API) CDMO Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Macromolecular API
Table 4. Major Players of Small Molecule API
Table 5. Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
Table 8. Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
Table 11. Global Active Pharmaceutical Ingredients (API) CDMO Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Player (2021-2026)
Table 13. Active Pharmaceutical Ingredients (API) CDMO Key Players Head office and Products Offered
Table 14. Active Pharmaceutical Ingredients (API) CDMO Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Region (2021-2026)
Table 19. Global Active Pharmaceutical Ingredients (API) CDMO Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Country (2021-2026)
Table 23. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
Table 25. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
Table 27. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Region (2021-2026)
Table 29. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Country (2021-2026)
Table 33. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Active Pharmaceutical Ingredients (API) CDMO
Table 39. Key Market Challenges & Risks of Active Pharmaceutical Ingredients (API) CDMO
Table 40. Key Industry Trends of Active Pharmaceutical Ingredients (API) CDMO
Table 41. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Recipharm Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 46. Recipharm Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 47. Recipharm Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Recipharm Main Business
Table 49. Recipharm Latest Developments
Table 50. Cambrex Corporation Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 51. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 52. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Cambrex Corporation Main Business
Table 54. Cambrex Corporation Latest Developments
Table 55. Patheon (Thermo Fisher Scientific) Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 56. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 57. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Patheon (Thermo Fisher Scientific) Main Business
Table 59. Patheon (Thermo Fisher Scientific) Latest Developments
Table 60. CordenPharma Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 61. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 62. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. CordenPharma Main Business
Table 64. CordenPharma Latest Developments
Table 65. Lonza Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 66. Lonza Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 67. Lonza Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Lonza Main Business
Table 69. Lonza Latest Developments
Table 70. Siegfried Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 71. Siegfried Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 72. Siegfried Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Siegfried Main Business
Table 74. Siegfried Latest Developments
Table 75. Catalent Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 76. Catalent Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 77. Catalent Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Catalent Main Business
Table 79. Catalent Latest Developments
Table 80. Boehringer Ingelheim Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 81. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 82. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Boehringer Ingelheim Main Business
Table 84. Boehringer Ingelheim Latest Developments
Table 85. Piramal Group Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 86. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 87. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Piramal Group Main Business
Table 89. Piramal Group Latest Developments
Table 90. AbbVie Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 91. AbbVie Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 92. AbbVie Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. AbbVie Main Business
Table 94. AbbVie Latest Developments
Table 95. SGS Quay Pharmaceuticals Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 96. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 97. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. SGS Quay Pharmaceuticals Main Business
Table 99. SGS Quay Pharmaceuticals Latest Developments
Table 100. Aenova Group Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 101. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 102. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Aenova Group Main Business
Table 104. Aenova Group Latest Developments
Table 105. Curia Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 106. Curia Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 107. Curia Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Curia Main Business
Table 109. Curia Latest Developments
Table 110. Sterling Pharma Solutions Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 111. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 112. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Sterling Pharma Solutions Main Business
Table 114. Sterling Pharma Solutions Latest Developments
Table 115. Eurofins CDMO Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 116. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 117. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Eurofins CDMO Main Business
Table 119. Eurofins CDMO Latest Developments
Table 1. Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Active Pharmaceutical Ingredients (API) CDMO Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Macromolecular API
Table 4. Major Players of Small Molecule API
Table 5. Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
Table 8. Active Pharmaceutical Ingredients (API) CDMO Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
Table 11. Global Active Pharmaceutical Ingredients (API) CDMO Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Player (2021-2026)
Table 13. Active Pharmaceutical Ingredients (API) CDMO Key Players Head office and Products Offered
Table 14. Active Pharmaceutical Ingredients (API) CDMO Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Region (2021-2026)
Table 19. Global Active Pharmaceutical Ingredients (API) CDMO Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Country (2021-2026)
Table 23. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
Table 25. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
Table 27. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Region (2021-2026)
Table 29. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Country (2021-2026)
Table 33. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Active Pharmaceutical Ingredients (API) CDMO
Table 39. Key Market Challenges & Risks of Active Pharmaceutical Ingredients (API) CDMO
Table 40. Key Industry Trends of Active Pharmaceutical Ingredients (API) CDMO
Table 41. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Recipharm Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 46. Recipharm Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 47. Recipharm Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Recipharm Main Business
Table 49. Recipharm Latest Developments
Table 50. Cambrex Corporation Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 51. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 52. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Cambrex Corporation Main Business
Table 54. Cambrex Corporation Latest Developments
Table 55. Patheon (Thermo Fisher Scientific) Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 56. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 57. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Patheon (Thermo Fisher Scientific) Main Business
Table 59. Patheon (Thermo Fisher Scientific) Latest Developments
Table 60. CordenPharma Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 61. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 62. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. CordenPharma Main Business
Table 64. CordenPharma Latest Developments
Table 65. Lonza Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 66. Lonza Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 67. Lonza Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Lonza Main Business
Table 69. Lonza Latest Developments
Table 70. Siegfried Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 71. Siegfried Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 72. Siegfried Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Siegfried Main Business
Table 74. Siegfried Latest Developments
Table 75. Catalent Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 76. Catalent Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 77. Catalent Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Catalent Main Business
Table 79. Catalent Latest Developments
Table 80. Boehringer Ingelheim Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 81. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 82. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Boehringer Ingelheim Main Business
Table 84. Boehringer Ingelheim Latest Developments
Table 85. Piramal Group Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 86. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 87. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Piramal Group Main Business
Table 89. Piramal Group Latest Developments
Table 90. AbbVie Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 91. AbbVie Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 92. AbbVie Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. AbbVie Main Business
Table 94. AbbVie Latest Developments
Table 95. SGS Quay Pharmaceuticals Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 96. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 97. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. SGS Quay Pharmaceuticals Main Business
Table 99. SGS Quay Pharmaceuticals Latest Developments
Table 100. Aenova Group Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 101. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 102. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Aenova Group Main Business
Table 104. Aenova Group Latest Developments
Table 105. Curia Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 106. Curia Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 107. Curia Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Curia Main Business
Table 109. Curia Latest Developments
Table 110. Sterling Pharma Solutions Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 111. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 112. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Sterling Pharma Solutions Main Business
Table 114. Sterling Pharma Solutions Latest Developments
Table 115. Eurofins CDMO Details, Company Type, Active Pharmaceutical Ingredients (API) CDMO Area Served and Its Competitors
Table 116. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product Offered
Table 117. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. Eurofins CDMO Main Business
Table 119. Eurofins CDMO Latest Developments
LIST OF FIGURES
Figure 1. Active Pharmaceutical Ingredients (API) CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Active Pharmaceutical Ingredients (API) CDMO Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Country/Region (2025)
Figure 8. Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type in 2025
Figure 10. Active Pharmaceutical Ingredients (API) CDMO in Clinical
Figure 11. Global Active Pharmaceutical Ingredients (API) CDMO Market: Clinical (2021-2026) & ($ millions)
Figure 12. Active Pharmaceutical Ingredients (API) CDMO in Commercial
Figure 13. Global Active Pharmaceutical Ingredients (API) CDMO Market: Commercial (2021-2026) & ($ millions)
Figure 14. Active Pharmaceutical Ingredients (API) CDMO in Others
Figure 15. Global Active Pharmaceutical Ingredients (API) CDMO Market: Others (2021-2026) & ($ millions)
Figure 16. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application in 2025
Figure 17. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Player in 2025
Figure 18. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Region (2021-2026)
Figure 19. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size 2021-2026 ($ millions)
Figure 20. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size 2021-2026 ($ millions)
Figure 21. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size 2021-2026 ($ millions)
Figure 23. Americas Active Pharmaceutical Ingredients (API) CDMO Value Market Share by Country in 2025
Figure 24. United States Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Region in 2025
Figure 29. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
Figure 30. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
Figure 31. China Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 35. India Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Country in 2025
Figure 38. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
Figure 39. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
Figure 40. Germany Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 41. France Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 54. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 55. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 57. United States Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 58. Canada Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 59. Mexico Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 60. Brazil Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 61. China Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 62. Japan Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 63. Korea Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 65. India Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 66. Australia Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 67. Germany Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 68. France Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 69. UK Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 70. Italy Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 71. Russia Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 72. Egypt Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 73. South Africa Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 74. Israel Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 75. Turkey Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 76. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 1. Active Pharmaceutical Ingredients (API) CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Active Pharmaceutical Ingredients (API) CDMO Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Country/Region (2025)
Figure 8. Active Pharmaceutical Ingredients (API) CDMO Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type in 2025
Figure 10. Active Pharmaceutical Ingredients (API) CDMO in Clinical
Figure 11. Global Active Pharmaceutical Ingredients (API) CDMO Market: Clinical (2021-2026) & ($ millions)
Figure 12. Active Pharmaceutical Ingredients (API) CDMO in Commercial
Figure 13. Global Active Pharmaceutical Ingredients (API) CDMO Market: Commercial (2021-2026) & ($ millions)
Figure 14. Active Pharmaceutical Ingredients (API) CDMO in Others
Figure 15. Global Active Pharmaceutical Ingredients (API) CDMO Market: Others (2021-2026) & ($ millions)
Figure 16. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application in 2025
Figure 17. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Player in 2025
Figure 18. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Region (2021-2026)
Figure 19. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size 2021-2026 ($ millions)
Figure 20. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size 2021-2026 ($ millions)
Figure 21. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size 2021-2026 ($ millions)
Figure 23. Americas Active Pharmaceutical Ingredients (API) CDMO Value Market Share by Country in 2025
Figure 24. United States Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Region in 2025
Figure 29. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
Figure 30. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
Figure 31. China Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 35. India Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Country in 2025
Figure 38. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
Figure 39. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
Figure 40. Germany Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 41. France Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Active Pharmaceutical Ingredients (API) CDMO Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 54. APAC Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 55. Europe Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 57. United States Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 58. Canada Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 59. Mexico Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 60. Brazil Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 61. China Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 62. Japan Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 63. Korea Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 65. India Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 66. Australia Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 67. Germany Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 68. France Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 69. UK Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 70. Italy Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 71. Russia Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 72. Egypt Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 73. South Africa Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 74. Israel Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 75. Turkey Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
Figure 76. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Active Pharmaceutical Ingredients (API) CDMO Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Active Pharmaceutical Ingredients (API) CDMO Market Size 2027-2032 ($ millions)
